The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical activity and safety of naptumomab estafenatox (NAP) and docetaxel in patients (pts) with checkpoint inhibitor (CPI) –pretreated advanced/metastatic non-small cell lung cancer (NSCLC): Preliminary results of a P2 trial.
 
Timothy Larson
No Relationships to Disclose
 
Robert M. Jotte
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Roche; Mirati Therapeutics
 
Ahmed Mohammed Fouad Abdelaziz
Employment - Arizona Oncology; Tenet Healthcare
 
Kartik Konduri
Consulting or Advisory Role - Amgen; AstraZeneca; EMD Serono; Jazz Pharmaceuticals; Lilly; Mirati Therapeutics; squibb; Takeda
Speakers' Bureau - Amgen; AstraZeneca; Bristol Myers Squibb
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Takeda
 
Donald A. Richards
Consulting or Advisory Role - Grail; Ipsen; Mirati Therapeutics; Roche/Genentech; Seattle Genetics/Astellas; Taiho Pharmaceutical
 
Michael W. Meshad
No Relationships to Disclose
 
Govardhanan Nagaiah
Honoraria - SOBI
Consulting or Advisory Role - BeiGene
Speakers' Bureau - Regeneron; SOBI
 
Alexander I. Spira
Leadership - Next Oncology (Inst)
Stock and Other Ownership Interests - Lilly
Honoraria - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Takeda
Consulting or Advisory Role - Amgen; Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Sanofi; Sanofi; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); Arch Therapeutics (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); Mirati Therapeutics (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Regeneron; Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst)
 
Pankaj Khandelwal
No Relationships to Disclose
 
Ilana Lorber
Employment - NeoTX
Honoraria - NeoTX
Travel, Accommodations, Expenses - NeoTX
 
Tal Hetzroni Kedem
Employment - NeoTX
Honoraria - NeoTX
Travel, Accommodations, Expenses - NeoX
 
Marcel Rozencweig
Employment - NeoTX
Leadership - NeoTX
Stock and Other Ownership Interests - NeoTX
Honoraria - Indena
Consulting or Advisory Role - Indena
Speakers' Bureau - Indena
Patents, Royalties, Other Intellectual Property - NeoTX
Travel, Accommodations, Expenses - NeoTX
Other Relationship - CryptoMedix
 
Scott Z. Fields
Employment - NeoTX (I)
Leadership - NeoTX; Ryvu Therapeutics
Stock and Other Ownership Interests - Bayer; Bayer; NeoTX; Vertex
Honoraria - Dark Blue; Ryvu Therapeutics
Consulting or Advisory Role - Dark Blue; Ryvu Therapeutics
Research Funding - NeoTX
Travel, Accommodations, Expenses - NeoTX